Health Trials

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

ConditionsPDACPDAC - Pancreatic Ductal AdenocarcinomaMetastatic Pancreas AdenocarcinomaPancreatic CancerPancreatic Cancer MetastaticPancreatic Adenocarcinoma MetastaticPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorRevolution Medicines, Inc.

About this trial

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.

Eligibility criteria

Qualifiers

At least 18 years old and has provided informed consent.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Histologically or cytologically confirmed PDAC with metastatic disease.

Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.

Disqualifiers

History of known central nervous system metastatic disease.

Concurrent systemic anticancer therapy.

Significant cardiovascular disease.

Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).

Trial design

Treatments tested in this trial

  • daraxonrasib

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Revolution Medicines, Inc.

Lead sponsor

Source ClinicalTrials.gov